Ads
related to: stepped care approach drugs for osteoporosis- Bone-Building Diet Guide
Read About The Best Foods For Bone
And AlgaeCal's Secret Weapon
- Pilates For Osteoporosis
Activate Your Stabilizing Muscles
With This Seven-Part Video Series
- Fracture Healing Guide
Six Tips for Healing Broken Bones
And Six Factors That Slow Healing
- Bone-Healthy Recipes
Experts Share Delicious Recipes
For Stronger, Healthier Bones
- Bone-Building Diet Guide
Search results
Results From The WOW.Com Content Network
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, [1] [2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium. [medical citation needed]
Osteoporosis is a very prevalent disease in the elderly population but not much is known about the optimal prescription and dosage of physical exercise to help prevent bone mineral loss. A lot of the focus around osteoporosis is also prevention and not so much maintenance which should be the front runner when considering what approach to take.
For premium support please call: 800-290-4726 more ways to reach us
Steroid-induced osteoporosis is osteoporosis arising from the use of glucocorticoids (a class of steroid hormones) analogous to Cushing's syndrome but involving mainly the axial skeleton. The synthetic glucocorticoid prescription drug prednisone is a main candidate after prolonged intake.
In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [38] under the brand name Prolia, [39] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [40] Denosumab is the first RANKL inhibitor to be approved by the FDA. [38]